Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Karuna Therapeutics

Hot Biotech Play Breaks Out Into By Range

As biotech stocks boom on a strong 2024 outlook following a rough two years, the XBI ETF launches a fresh breakout.

Investors Business Daily

Bristol Myers Squibb Acquires Karuna Therapeutics in Billion Deal

Bristol Myers Squibb is set to acquire Karuna Therapeutics in a billion deal, expanding its neuroscience portfolio with the promising antipsychotic dru...

Top News

Bristol Myers Squibb acquires Karuna Therapeutics for $14 billion, boosting neuroscience portfolio

Drugmaker Bristol Myers Squibb is acquiring Karuna Therapeutics, a biopharmaceutical company that has developed a new antipsychotic, in a $14 billion deal

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Bristol's $14 Billion Takeover Of Karuna Pulled A Bevy Of Stocks Higher

Bristol Myers Squibb announced its $14 billion acquisition of Karuna Therapeutics on Friday, sending KRTX stock into the stratosphere.

Investors Business Daily

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimer's drugmaker Karuna Therapeutics for $14 billion.

The Street

Karuna Takes A Big Step In Schizophrenia Treatment. But Shares Yo-Yo.

Karuna Therapeutics asked the Food and Drug Administration to approve its schizophrenia treatment on Thursday, and KRTX stock rose.

Investors Business Daily

‘We have hope for some breakthroughs’: can we change the way we treat schizophrenia?

Scientists are cautiously optimistic that new approaches to treating the disabling condition may improve the lives of those affected by it

The Guardian - UK

Read news from The Economist, FT, and more,
with one subscription

Karuna Reverses 12% Premarket Gain And Skids To 7-Month Low

Karuna said Monday a third study of its schizophrenia drug succeeded, but KRTX stock reversed early gains and toppled to a seven-month low.

Investors Business Daily

People

Andrew Miller

78 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

ACADIA Pharmaceuticals

20 stories

Karuna

12 stories

Arrowhead Pharmaceuticals

10 stories

XBI

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.